Senseonics begins human testing of implantable Freedom glucose monitor

Senseonics has started the first human study of Freedom, an implanted glucose monitor designed to track blood sugar for up to a year without any skin-worn transmitter. Battery and Bluetooth are built into the sensor, sending readings straight to a smartphone, with a commercial launch targeted for 2028.

• Freedom packs sensor, battery and Bluetooth into a single implant
• Preclinical tests showed 100% communication success across 18,500 data points
• Pivotal trial planned for 2027, commercial launch targeted for 2028
• Unclear whether standalone alerts work when the phone is out of range